gov.uk· MHRA (UK)·· 20 hours agoPickScore89
MHRA approves new oral treatment for moderate to severe plaque psoriasis
In brief
The UK MHRA approved icotrokinra hydrochloride (Icotyde) on 23 October 2026 for patients aged 12 years and older weighing at least 40 kg with moderate to severe plaque psoriasis.
Why it matters
MHRA approval of the first oral IL-23 receptor antagonist for plaque psoriasis, supported by four Phase 3 trials.
Source: gov.uk · gov.uk